Nigeria Tightens API Sourcing Norms For Finished Pharma Products

Hyderabad: “Pharmaceutical companies and manufacturers must prioritise sourcing APIs from reputable suppliers while adhering to stringent quality control measures to ensure the highest standards in their products,” Nigerian regulator National Agency for Food and Drug Administration and Control said, listing the approved sources and setting timeline for compliance.

While January 2024 was when the directive came into force for those submitting dossiers for product registration, companies with registered finished pharmaceutical products (FPPs) who have not sourced the APIs or excipients from listed sources are required to comply by January 2027, it said in a communication that Pharmaceuticals Export Promotion Council of India has circulated to its members.

Nigeria is 10th largest pharma export destination for India. Pharma exports to Nigeria increased 2.65% from $573.17 million in 2020-21 to $588.34 million in 2021-22. In 2022-23, it declined 12.30% to $515.96 million or 2.03% of the total pharma exports from India, Pharmexcil data shows.

Related Posts

  • Pharma
  • February 17, 2025
  • 82 views
GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gained by 20 percent on Monday, February 17, as brokerages like ICICI Securities and Motilal Oswal continue to maintain positive rating of the stock. GlaxoSmithKline Pharmaceuticals Ltd…

  • Pharma
  • February 17, 2025
  • 73 views
Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Shares of Glenmark Pharmaceuticals Ltd rose 4% on February 17 after the firm gave a strong guidance for FY26 and it returned to black in the December quarter. The drugmaker…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wow! What a Change of Heart in Practitioners of Allopathy!

Wow! What a Change of Heart in Practitioners of Allopathy!

GSK Pharma shares gain 20% following strong Q3FY25 results

GSK Pharma shares gain 20% following strong Q3FY25 results

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

Glenmark Pharma shares rise 4% on Q3 results, FY26 guidance

US Tariffs on pharma: What are the potential impact on Indian drugmakers

US Tariffs on pharma: What are the potential impact on Indian drugmakers

Twin Health bats a1000 before enters Digital Health NY 100

Twin Health bats a1000 before enters Digital Health NY 100

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%

US tariff jitters rock pharma stocks; Sun Pharma, Lupin, Dr Reddy’s slump 2-4%